Are Mushrooms Anti-Inflammatory? The Science Explained

Mushrooms contain a range of compounds that reduce markers of inflammation in laboratory settings, and a smaller but growing body of human evidence suggests that eating certain species can shift the immune system toward a less inflammatory state. The story is not as simple as “mushrooms fight inflammation,” though, because the same compounds that calm one arm of the immune response can activate another. Understanding which mushrooms do what, how cooking affects their chemistry, and where human data falls short of the lab results gives a much clearer picture than the headline claim alone.

What Makes Mushrooms Anti-Inflammatory in the First Place

Mushrooms produce a remarkably diverse set of bioactive molecules. The compounds most studied for anti-inflammatory effects fall into a few major categories: polysaccharides (especially beta-glucans), terpenoids, phenolic compounds, and smaller molecules like ergothioneine.¹ Each of these works through different mechanisms, and the balance between them varies wildly from one mushroom species to the next.

Beta-glucans are probably the most discussed. These are long-chain sugars embedded in mushroom cell walls. They interact with specific immune receptors called Dectin-1 and Toll-like receptors on the surface of immune cells.² That interaction is where things get interesting and a bit paradoxical. Beta-glucans do not simply suppress inflammation. They prime the immune system, waking up macrophages and other white blood cells. In some situations that leads to the release of pro-inflammatory signals; in others, it helps the body resolve inflammation more efficiently. Whether the net effect leans toward calming or stimulating depends on the branching structure of the beta-glucan, the dose, and what else is happening in the immune environment at the time.

Triterpenes, found in high concentrations in reishi (Ganoderma lucidum) and some other medicinal species, act more like classic anti-inflammatory agents. In cell studies, triterpenes from reishi reduced the production of key inflammatory enzymes and signaling molecules in a dose-dependent fashion.³ They also suppressed the expression of COX-2, the same enzyme that drugs like ibuprofen target.⁴ That is a striking finding, though it comes from cells in a dish, not from people taking reishi supplements.

Ergothioneine deserves separate mention because the human body has a dedicated transporter protein just to absorb it, which is unusual for a dietary compound. Mushrooms are the richest dietary source of ergothioneine, and research on the transporter shows that when it is absent in animal models, oxidative stress and inflammation worsen, especially in the gut, liver, and lungs.⁵ The existence of a specialized uptake system hints that the body evolved to use this molecule, and that dietary intake may genuinely matter for keeping inflammation in check.

The Immunomodulation Paradox

One reason the mushroom-inflammation story is confusing is that mushrooms are often described as immunomodulators, not straight immunosuppressants. That distinction matters. An immunosuppressant drug dials the immune system down. An immunomodulator adjusts it, turning certain pathways up while turning others down.

Beta-glucans from reishi, for example, bind to Dectin-1 on macrophages and trigger the release of several cytokines, including some pro-inflammatory ones like TNF-alpha and IL-6.⁶ At face value, that sounds inflammatory, not anti-inflammatory. But the same study found that the signaling depended on a master switch called NF-kB. When NF-kB was blocked, those inflammatory cytokines dropped sharply. The picture that emerges is of a system being trained and tuned, not simply suppressed.

A beta-glucan from maitake mushroom tells a similar story. It binds Dectin-1 and activates a signaling cascade that can trigger TNF-alpha release, but through a pathway that also plays a role in anti-tumor immune responses.⁷ This dual nature is why you will sometimes see research on mushrooms filed under “immune boosting” and “anti-inflammatory” in the same paper. Both descriptions can be accurate, depending on which arm of the immune response you are measuring.

Research on a medicinal mushroom blend illustrated the complexity further. Different fractions of the same blend had different effects: the solid fraction most potently activated pro-inflammatory and antiviral cytokines, while the aqueous fraction leaned more toward anti-inflammatory and regenerative signaling.⁸ How you process and extract a mushroom changes whether it acts more as an immune activator or an inflammation reducer.

What Human Studies Actually Show

Lab studies using isolated cells or animal models offer a strong foundation, but human trials are where things get real. And the human data on mushrooms and inflammation is frankly mixed.

The most encouraging result comes from a randomized dietary intervention in healthy young adults who ate shiitake mushrooms daily for four weeks. After the intervention, participants showed higher levels of anti-inflammatory signaling molecules (IL-4 and IL-10), lower levels of a chemokine associated with inflammation (MIP-1α), and reduced C-reactive protein, a standard blood marker for systemic inflammation. The researchers concluded that the overall cytokine pattern shifted toward a less inflammatory state.⁹ That is a genuinely interesting finding, though it was a small trial in young, healthy people who may not represent the general population.

On the other end, a randomized controlled trial in patients with type 2 diabetes looked at whether white button mushroom powder would lower inflammatory biomarkers. It did not. There was no significant difference in high-sensitivity C-reactive protein or IL-6 between the mushroom group and controls after the study period.¹⁰ This does not mean white button mushrooms are useless. The dose, form (dried powder versus fresh), population studied (people with established metabolic disease), and duration all affect results. But it does caution against assuming that any mushroom in any form will move the needle on inflammation in everyone.

The gap between strong lab findings and modest or mixed human outcomes is one of the honest truths about mushroom research. Most of the dramatic anti-inflammatory effects you will see cited online come from cell studies or animal experiments. Human trials are fewer, smaller, and more variable. That does not invalidate the science; it just means we are still early in understanding which mushrooms, at what doses, for which people, produce clinically meaningful anti-inflammatory effects.

Species Differences Are Bigger Than You Might Think

Talking about “mushrooms” as a single category is a bit like talking about “plants.” The white button mushroom sitting on a grocery store shelf and the lion’s mane growing on a hardwood log are separated by millions of years of evolution and produce very different chemical profiles.

Lion’s mane (Hericium erinaceus) has attracted particular attention for its effects on brain inflammation. In laboratory studies using hippocampal neurons and brain immune cells, lion’s mane extracts markedly reduced nitric oxide production triggered by inflammatory stimulation, cutting it roughly in half at the highest concentrations tested.¹¹ That is promising for neuroinflammation research, though again, this was in cultured cells, not in human brains.

Cordyceps militaris, a parasitic fungus popular in traditional medicine, showed topical anti-inflammatory effects in mouse models of ear edema and also demonstrated antioxidant and pain-reducing properties.¹² Reishi, as noted above, delivers triterpenes that act on the COX-2 pathway. King oyster, shiitake, and maitake each bring their own mix of beta-glucan structures with different branching patterns, which leads to measurably different receptor activation.²

Even within the common grocery species, there are meaningful differences. A study on how various mushrooms affect vascular inflammation found that white button mushrooms consistently reduced adhesion molecules on endothelial cells (the molecules that let inflammatory white blood cells stick to blood vessel walls), while specialty mushrooms like shiitake and oyster modulated those same molecules in more variable patterns.¹³ All mushrooms tested reduced monocyte binding to blood vessel cells, but through partially different mechanisms. If you are eating mushrooms in part for their potential anti-inflammatory effects, variety is probably a smart strategy.

The Gut Connection

Some of the anti-inflammatory benefit from eating mushrooms may not come from the compounds being absorbed directly into your bloodstream. Instead, it may come from what happens in your gut. Mushroom fiber, including beta-glucans that survive digestion, feeds beneficial gut bacteria. Those bacteria ferment the fiber and produce short-chain fatty acids, which are potent local anti-inflammatory signals in the intestinal lining and also enter the bloodstream to affect distant tissues.

A pilot clinical study in healthy volunteers found that dietary supplementation with a mix of mushroom species increased short-chain fatty acid production and was associated with higher levels of secretory IgA, an antibody that helps maintain gut barrier integrity.¹⁴ The researchers noted that the beta-glucans in the mushrooms were likely being metabolized by gut microbiota, making this an indirect rather than direct mechanism. This gut-mediated pathway is especially relevant because low-grade intestinal inflammation underlies many chronic conditions, and improving the gut environment may have downstream effects that standard blood tests for inflammation do not fully capture.

How Cooking Affects Anti-Inflammatory Compounds

If you are eating mushrooms primarily for their bioactive compounds, how you cook them matters more than most people realize. Different cooking methods protect or destroy different molecules, and there is no single “best” approach for everything at once.

A study comparing common household cooking methods for white button and shiitake mushrooms found that boiling actually increased the concentration of beta-glucans and ergosterol (a precursor to vitamin D2) but caused significant losses of phenolic compounds. Frying did the opposite: it reduced beta-glucan and ergosterol content but protected phenolics from breaking down.¹⁵ If you are after beta-glucans for immune modulation, boiling or including the cooking liquid (as in a soup) is the better bet. If you want to preserve the broader antioxidant phenolics, a quick sauté in oil has the advantage.

Temperature also matters for roasting. Shiitake mushrooms roasted at around 140°C for an hour showed the highest antioxidant activity and phenolic content, while beta-glucan levels peaked at about 120°C.¹⁶ High-temperature roasting above 160°C began to degrade both classes of compounds. The practical takeaway is that moderate heat preserves more of the good stuff; charring your mushrooms until crispy may taste great but likely costs you some of the anti-inflammatory potential.

There is also the vitamin D angle. Mushrooms that have been exposed to UV light (either sunlight or commercial UV treatment) convert ergosterol to vitamin D2.¹⁷ Vitamin D itself has well-documented anti-inflammatory roles in the body. UV-exposed mushrooms can contain meaningful amounts of vitamin D2, though the level varies hugely depending on species and treatment. Placing store-bought mushrooms gill-side up in sunlight for 30 to 60 minutes before cooking can substantially boost their vitamin D2 content, which is a simple practical step that most people overlook.

Mushrooms and Skin Inflammation

One of the more tangible applications of mushroom anti-inflammatory research has been in dermatology, particularly for atopic dermatitis (eczema). The evidence here comes from both animal models and at least one human trial, which puts it ahead of many other mushroom-health claims.

In a mouse model of atopic dermatitis, extracts from king oyster mushroom (Pleurotus eryngii) applied topically reduced skin thickness, mast cell infiltration, and the expression of multiple inflammatory cytokines. The extract appeared to rebalance the two arms of the adaptive immune response (Th1 and Th2), which are characteristically skewed in eczema.¹⁸ Chaga mushroom (Inonotus obliquus) showed similar effects in a comparable mouse model, with significant reductions in inflammatory cytokine expression in skin lesions.¹⁹

More compelling is a human trial of a beta-glucan cream derived from oyster mushroom (Pleurotus ostreatus) used as a supportive treatment for mild-to-moderate atopic dermatitis. In a split-body design where each participant applied the active cream on one side and a comparator on the other, the beta-glucan side showed significantly fewer days of eczema flares, lower severity scores, and reduced itching.²⁰ This is not a cure for eczema, and it was studied as supportive care alongside standard treatment. But a well-designed human trial showing measurable symptom improvement is a notable step beyond the lab bench.

Why the Supplement Market Outpaces the Science

Walk through any health food store and you will find mushroom supplements marketed for immune support, inflammation, brain health, and a dozen other claims. The research base is real but narrower than the marketing implies. Reviews of the field have pointed out that before mushroom-derived immunomodulatory compounds can be widely used as therapeutic agents, several problems need to be solved, including standardization of extracts, understanding of dose-response relationships in humans, and better-designed clinical trials.²¹

One practical issue is that supplement labels rarely specify the beta-glucan content, the extraction method, or which part of the mushroom (fruiting body versus mycelium) was used. These details matter enormously. A supplement made from mycelium grown on grain may contain mostly starch with minimal bioactive compounds, while an extract from fruiting bodies using hot water or ethanol would have a very different chemical profile. The same species processed two different ways can behave as two fundamentally different products in terms of immune effects.

For people who just want to eat more mushrooms as part of a healthy diet, the bar is lower. There is no plausible harm from including a variety of culinary mushrooms in regular meals, and the combination of fiber, micronutrients, ergothioneine, and beta-glucans is at minimum nutritionally sound. Whether that dietary pattern produces clinically measurable reductions in inflammatory markers depends on the person, the mushrooms, and probably a dozen other variables that current research has not fully teased apart. The science is legitimately promising but still catching up to the enthusiasm.